Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.75 +1.73%

+$0.14 today

Market cap
$56.57M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.63M

Average 0.42M

CRBP Long-term Investments

Investments the company intends to hold for more than a year.

Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP

Long-term Investments · Q1 FY2026 · quarter ended Mar 2026

Long-term investments remains negative

Q1 FY2026 long-term investments was $0, compared with $0 a year earlier.

Context

  • Long-term investments amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Long-term investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Long-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Investments history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Long-term Investments vs competitors

How CRBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term investments is compared through growth and share of total assets rather than absolute size.
  • Long-term investments amounts to 0.0% of total assets for CRBP, versus a peer median of 0.0%.
CRBP Competitors
Long-term Investments for CRBP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IPHAInnate Pharma S.A.Dec 2025€10.7M EUR+4.1%-32.7%17.1%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$0 USD——0.0%
FBRXForte Biosciences, Inc.Mar 2026$0 USD——0.0%
ALECAlector, Inc.Mar 2026$0 USD——0.0%
PEPGPepGen Inc.Mar 2026$0 USD——0.0%
MOLNMolecular Partners AGMar 2026CHF 0 CHF——0.0%
MISTMilestone Pharmaceuticals Inc.Mar 2026$0 USD——0.0%
CRDFCardiff Oncology, Inc.Mar 2026$0 USD——0.0%
RANIRani Therapeutics Holdings, Inc.Mar 2026$0 USD——0.0%
ELTXElicio Therapeutics, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding CRBP) —+4.1%-32.7%0.0%

Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.01M17M13.72M17.2M28.49M
Short-term Investments72.64M42.19M7.18M131.86M134.78M
Net Receivables00001.5M
Inventory00000
Other Current Assets192.48K192.48K192K3.91M1.52M
Total Current Assets100.2M60.18M23.55M152.98M166.95M
Property, Plant & Equipment (Net)7M5.5M4.04M2.52M1.24M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets523.81K632.77K690K385K0
Total Non-current Assets7.53M6.13M4.73M2.9M1.24M
Total Assets107.73M66.31M28.27M155.88M168.2M
Account Payables1.78M2.17M3.18M4.79M2.22M
Short-term Debt3.86M3.15M16.21M00
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities133.71K36.87K39K2.28M2.86M
Total Current Liabilities17.01M12.64M31.89M11.82M20.69M
Long-term Debt15.64M15.98M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities22.21K22.21K44K00
Total Non-current Liabilities21.61M20.68M3.28M1.63M0
Total Liabilities38.62M33.32M35.18M13.45M20.69M
Common Stock12.52K41701K2K
Retained Earnings(349.73M)(392.08M)(436.68M)(476.89M)(555.43M)
Accumulated OCI(62.45K)(126.09K)(1K)35K(53K)
Other Stockholders Equity00(0)00
Minority Interest00000
Total Equity69.11M32.99M(6.91M)142.43M147.5M
Total Debt26.59M25.09M20.89M3.24M1.63M
Net Debt1.58M8.09M7.16M(13.96M)(26.86M)

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Intrinsic Alpha fair value

Locked

Current Price

$2.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.